 |
| BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement. SmallCapVoice.com, Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence. |
|
   |
| BCTXF Announces Conference Call to Update Investors on Key Findings |
|
 Hot Stock to Watch |
Company: BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX-V: BCT)
|
Last:
Price: 0.128
Change (%): + 0.00 (0.00)
Volume: 0 |
 |
BriaCell to Hold Conference Call on Key Clinical Findings; Activities
BERKELEY, Calif. and VANCOUVER, British Columbia, June 21, 2018 (GLOBE NEWSWIRE) - BriaCell Therapeutics Corp. (“BriaCell”) (OTCQB: BCTXF) (TSX-V: BCT), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to provide a Corporate Update on its activities and new developments, including positive Phase IIa safety information, discovery of tumor shrinkage mechanism, and patient enrollment acceleration.
Dr. Williams, BriaCell’s President & CEO, will be available to answer questions following the presentation on:
Date: June 28, 2018 at 11:00 AM ET
Dial-In Numbers:
Canada: 1-647-722-6839
United States: 1-303-248-0285
Access Code: 5147677
Webinar Access (at the time of event): http://www.readytalk.com/join (Access code: 5147677)
“We are very excited to have hit several important milestones for BriaCell and want to share our plans and the key objectives coming up. Our development of a novel personalized targeted immunotherapy that is off-the-shelf without the costs associated with other personalized approaches positions BriaCell to revolutionize the treatment of advanced breast cancer patients. This novel targeted approach and the excellent safety profile we have seen to date should make BriaCell an attractive collaborator for a large number of large and medium sized pharmaceutical companies focusing on immuno-oncology. We will continue to work tirelessly to improve patient outcomes in the fight against this deadly disease, ” stated Dr. Williams, BriaCell’s President & CEO.
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
